The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. While both https://geraldmzuy797059.slypage.com/39655453/glp-3-retatrutide-a-comparative-analysis